May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Topical COX-2 Inhibitor Decreases the Expression of C-Met in Uveal Melanoma
Author Affiliations & Notes
  • S. Bakalian
    Ophthal-HCW Ocular Pathol Lab, McGill University, Montreal, Quebec, Canada
  • E. Antecka
    Ophthal-HCW Ocular Pathol Lab, McGill University, Montreal, Quebec, Canada
  • D. Faingold
    Ophthal-HCW Ocular Pathol Lab, McGill University, Montreal, Quebec, Canada
  • C. Martins
    Ophthal-HCW Ocular Pathol Lab, McGill University, Montreal, Quebec, Canada
  • E. Castiglione
    Ophthal-HCW Ocular Pathol Lab, McGill University, Montreal, Quebec, Canada
    Departamento de Oftalmologia, Pontificia Universidad Catolica de Chile, Santiago, Chile
  • M. N. Burnier, Jr.
    Ophthal-HCW Ocular Pathol Lab, McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  S. Bakalian, None; E. Antecka, None; D. Faingold, None; C. Martins, None; E. Castiglione, None; M.N. Burnier, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 63. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Bakalian, E. Antecka, D. Faingold, C. Martins, E. Castiglione, M. N. Burnier, Jr.; Topical COX-2 Inhibitor Decreases the Expression of C-Met in Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):63. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Expression of C-Met has been shown to be correlated with mortality in uveal melanoma (UM) patients. In addition, the expression of cyclooxygenase-2 (COX-2) has been reported to be an indicator of poor prognosis in a wide variety of tumors, including UM. Previous work demonstrated that a COX-2 inhibitor (Nepafenac) could delay the progression of UM, including development of metastatic disease, in a rabbit model. The aim of this study was to investigate the expression of C-Met in the intraocular tumors of non-treated and Nepafenac-treated animals. Furthermore, we evaluated the expression of C-Met mRNA in non-treated and treated human UM cell lines.

Methods: : Twenty-eight New Zealand albino rabbits were divided into two equal groups. The experimental group received eye drops containing 0.3% Nepafenac solution while the control group received a placebo. Two drops were administered twice daily for the duration of the 12-week experiment. One animal per group was sacrificed each week for histopathological studies. Paraffin-embedded primary intraocular tumor sections from each of the 28 animals were immunostained with a C-Met monoclonal antibody. The immunostaining was evaluated semi-quantitatively based on staining extent and intensity. The expression levels of C-Met mRNA were also assessed in five human UM cell lines (92.1, OCM-1, SP6.5, MKT-BR, and UW-1) before and after treatment with Amfenac, the active metabolite of Nepafenac, using quantitative real-time PCR.

Results: : All intraocular tumors stained positive, to varying degrees for C-Met expression. The immunostaining was cytoplasmic in all samples. The intensity of immunostaining was significantly higher in the primary tumors of all non-treated rabbits when compared to the Nepafenac-treated group. All five human UM cell lines expressed different levels of C-Met mRNA, however, the expression was always higher in non-treated cell lines compared to treated cell lines. There was up to a four-fold decrease in the expression levels of C-Met mRNA after treatment with Amfenac.

Keywords: melanoma • immunohistochemistry • uvea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×